BioRestorative Therapies faces a precarious financial outlook characterized by erratic, non-recurring revenue streams and a heavy reliance on equity-dilutive financing to sustain its R&D-intensive clinical programs.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
Biorestorative Therapies, Inc. (NASDAQ: BRTX - Get Free Report) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 11,586 shares, a decrease of 69.2% from the August 31st total of 37,641 shares. Currently, 1.0% of the company's stock are short sold.
MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
Benchmark BRTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioRestorative Therapies, Inc. (BRTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.52 | $1.35M | -0.12 | -10.3% | -3089.55% | -423.84% | — | |
| $14.27 | $1.85B | -32.20 | 602.33% | -47.82% | -10.06% | — | |
| $0.29 | $40.59M | -3.64 | 14.21% | -10.17% | -23.45% | — | |
| $3.31 | $482.47M | -25.15 | 19.99% | -6.32% | -8.29% | — | |
| $173.49 | $9.79B | -831.29 | 16.36% | -1.47% | -0.56% | — | |
| $53.69 | $6.68B | -9.60 | 376.56% | -667.26% | — | — |
BioRestorative Therapies, Inc. (BRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioRestorative Therapies, Inc. (BRTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Jul 16, 2026·SEC
Jun 12, 2026·SEC
Get notified when BRTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioRestorative Therapies, Inc. (BRTX) stock FAQ — growth, dividends, profitability & financials explained
BioRestorative Therapies, Inc. (BRTX) reported $0.4M in revenue over the trailing twelve months. Revenue was $0.4M in fiscal year 2025.
BioRestorative Therapies, Inc. (BRTX) revenue fell by 8.5% over the trailing twelve months, compared with the twelve months before.
No. BioRestorative Therapies, Inc. (BRTX) reported a net loss of $11.1M over the trailing twelve months.
BioRestorative Therapies, Inc. (BRTX) had a return on equity (ROE) of -423.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
BioRestorative Therapies, Inc. (BRTX) had negative free cash flow of $11.9M over the trailing twelve months.
